148 related articles for article (PubMed ID: 38335467)
1. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer CE; Blum JL; Yothers G; Asmar L; Flynn PJ; Robert NJ; Hopkins JO; O'Shaughnessy JA; Rastogi P; Puhalla SL; Hilton CJ; Dang CT; Gómez HL; Vukelja SJ; Lyss AP; Paul D; Brufsky AM; Colangelo LH; Swain SM; Mamounas EP; Wolmark N
J Clin Oncol; 2024 Apr; 42(12):1344-1349. PubMed ID: 38335467
[No Abstract] [Full Text] [Related]
2. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Blum JL; Flynn PJ; Yothers G; Asmar L; Geyer CE; Jacobs SA; Robert NJ; Hopkins JO; O'Shaughnessy JA; Dang CT; Gómez HL; Fehrenbacher L; Vukelja SJ; Lyss AP; Paul D; Brufsky AM; Jeong JH; Colangelo LH; Swain SM; Mamounas EP; Jones SE; Wolmark N
J Clin Oncol; 2017 Aug; 35(23):2647-2655. PubMed ID: 28398846
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
[No Abstract] [Full Text] [Related]
4. Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Geyer CE; Bandos H; Rastogi P; Jacobs SA; Robidoux A; Fehrenbacher L; Ward PJ; Polikoff J; Brufsky AM; Provencher L; Paterson AHG; Hamm JT; Carolla RL; Baez-Diaz L; Julian TB; Swain SM; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2022 Jun; 193(3):555-564. PubMed ID: 35230585
[TBL] [Abstract][Full Text] [Related]
5. Taxanes for adjuvant treatment of early breast cancer.
Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
[TBL] [Abstract][Full Text] [Related]
6. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A; van Ramshorst MS; van Werkhoven ED; Mandjes IA; Kemper I; Vulink AJ; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS
JAMA Oncol; 2021 Jul; 7(7):978-984. PubMed ID: 34014249
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis.
Ding W; Li Z; Wang C; Dai J; Ruan G; Tu C
Medicine (Baltimore); 2018 Oct; 97(42):e12908. PubMed ID: 30335021
[TBL] [Abstract][Full Text] [Related]
8. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
Pal SK; Childs BH; Pegram M
Breast Cancer Res Treat; 2010 Jan; 119(1):25-32. PubMed ID: 19795206
[TBL] [Abstract][Full Text] [Related]
9. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
; Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K
Lancet; 2012 Feb; 379(9814):432-44. PubMed ID: 22152853
[TBL] [Abstract][Full Text] [Related]
10. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
Shah AN; Gradishar WJ
Oncologist; 2018 Oct; 23(10):1153-1161. PubMed ID: 30120159
[TBL] [Abstract][Full Text] [Related]
13. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
14. Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
Conte P; Bisagni G; Piacentini F; Sarti S; Minichillo S; Anselmi E; Aieta M; Gebbia V; Schirone A; Musolino A; Garrone O; Beano A; Rimanti A; Giotta F; Turletti A; Miglietta F; Dieci MV; Vicini R; Balduzzi S; D'Amico R; Guarneri V
J Clin Oncol; 2023 Nov; 41(32):4976-4981. PubMed ID: 37748109
[No Abstract] [Full Text] [Related]
15. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
;
Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
[TBL] [Abstract][Full Text] [Related]
17. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
18. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
19. The role of anthracyclines in the treatment of early breast cancer.
Greene J; Hennessy B
J Oncol Pharm Pract; 2015 Jun; 21(3):201-12. PubMed ID: 24769570
[TBL] [Abstract][Full Text] [Related]
20. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials.
Zheng R; Han S; Duan C; Chen K; You Z; Jia J; Lin S; Liang L; Liu A; Long H; Wang S
Medicine (Baltimore); 2015 May; 94(17):e803. PubMed ID: 25929935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]